 FINANCIAL HIGHLIGHTS
BUSINESS HIGHLIGHTS
• Reverse takeover and re-admission of enlarged Group to AIM.
• Expanded research programmes in schizophrenia and bipolar disorder.
• Management team enlarged.
• Identiﬁcation of four unique patient subgroups in schizophrenia
and bipolar disorder.
Year ended
 31 December 2006
Year ended
31 December 2005
Research and Development expenditure £304,712 £123,212
Group Operating Loss £976,558 £224,716
Group Loss Before Tax £945,036 £224,716
Loss per Share 0.24 pence 0.18 pence
Cash out ﬂow from operating activities £627,291 £245,049
4
